Viking Therapeutics, Inc. (VKTX)
33.98
+0.48
(+1.43%)
USD |
NASDAQ |
Sep 03, 12:54
Viking Therapeutics Research and Development Expense (TTM) : 509.32M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 509.32M |
| March 31, 2026 | 453.72M |
| December 31, 2025 | 344.96M |
| September 30, 2025 | 222.48M |
| June 30, 2025 | 155.32M |
| March 31, 2025 | 118.93M |
| December 31, 2024 | 101.64M |
| September 30, 2024 | 91.16M |
| June 30, 2024 | 86.75M |
| March 31, 2024 | 76.90M |
| December 31, 2023 | 63.81M |
| September 30, 2023 | 59.48M |
| June 30, 2023 | 53.06M |
| March 31, 2023 | 52.69M |
| December 31, 2022 | 54.23M |
| September 30, 2022 | 47.90M |
| June 30, 2022 | 46.74M |
| March 31, 2022 | 46.00M |
| December 31, 2021 | 44.98M |
| September 30, 2021 | 44.18M |
| June 30, 2021 | 40.50M |
| March 31, 2021 | 35.48M |
| December 31, 2020 | 31.93M |
| September 30, 2020 | 29.33M |
| Date | Value |
|---|---|
| June 30, 2020 | 27.50M |
| March 31, 2020 | 27.05M |
| December 31, 2019 | 23.56M |
| September 30, 2019 | 22.20M |
| June 30, 2019 | 22.60M |
| March 31, 2019 | 20.49M |
| December 31, 2018 | 19.04M |
| September 30, 2018 | 16.98M |
| June 30, 2018 | 14.76M |
| March 31, 2018 | 13.26M |
| December 31, 2017 | 13.74M |
| September 30, 2017 | 13.36M |
| June 30, 2017 | 12.00M |
| March 31, 2017 | 10.65M |
| December 31, 2016 | 9.000M |
| September 30, 2016 | 9.572M |
| June 30, 2016 | 9.975M |
| March 31, 2016 | 8.705M |
| December 31, 2015 | 6.967M |
| September 30, 2015 | 24.99M |
| June 30, 2015 | 22.53M |
| March 31, 2015 | 21.43M |
| June 30, 2014 | 21.30M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Vertex Pharmaceuticals, Inc. | 3.907B |
| Eli Lilly & Co. | 14.60B |
| Regeneron Pharmaceuticals, Inc. | 5.748B |
| Skye Bioscience, Inc. | 32.02M |
| Eledon Pharmaceuticals, Inc. | 67.89M |